UNSPSC 51314316: Azatadine/pseudoephedrine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE501. This VA Drug Class (RE501) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT.

UNSPSC 51314316 Azatadine/pseudoephedrine is a Commodity code that nominally designates a specific pharmaceutical combination product, but recent state and local procurement activity under this code shows minimal relevance to the code's stated scope. The three most recent opportunities tagged to this code involve naloxone and drug deactivation systems (Seminole County, Florida), a therapeutic pharmacy initiative for direct-to-manufacturer prescription programs (Texas Health and Human Services Commission), and generic multi-source pharmaceuticals and OTC products through a cooperative purchasing vehicle (Minnesota Multistate Cooperative Purchasing Alliance). None of these solicitations specifically concern azatadine/pseudoephedrine formulations; instead, they reflect broader pharmaceutical procurement across emergency response supplies, state pharmacy benefit design, and multi-jurisdiction generic drug distribution. The code appears to be a catch-all taxonomy tag within state and local systems for pharmaceutical commodities, suggesting either miscoding in source systems or that jurisdictions use this Commodity code as a parent classification for diverse pharmaceutical line items rather than as a precise product identifier.

Activity spans Florida county health departments, state HHS agencies, and regional cooperative purchasing organizations. The most concrete recent opportunity is Seminole County's IFB 60459723LAS (posted June 30, 2026, response deadline July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, fixed-fee pricing, and a two-year initial term with one-year renewal option. Texas HHS issued an RFI (HHS0017013, April 3, 2026) to gather market intelligence on direct-to-manufacturer prescription contracting before a formal RFP. Minnesota's MMCAP (cooperative purchasing for Minnesota Department of Administration and participating jurisdictions including Oregon) released an RFP (S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products through three authorized wholesalers, with awards effective July 1, 2026, and 75 percent evaluation weight on price competitiveness. Vendors pursuing this code should treat it as a general pharmaceutical category rather than a specific drug formulation and expect to bid into state agency health programs, county emergency preparedness initiatives, and multi-state cooperative purchasing arrangements.